Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epzicom Switch for HIV with Decreasing CD4
NCT01608269Phase 4
Key facts
- Status
- Completed
- Start
- Nov 2010
- Primary completion
- Oct 2012
- Countries
- 1
- Modality
- Small Molecules
- Conditions
- human immunodeficiency virus infection (HIV)
01
Overview
Phase 4, open-label, single-arm trial of abacavir + lamivudine in human immunodeficiency virus infection (HIV). Primary endpoint: Efficacy at 1 year. Started Nov 2010; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
ABC/3TC (Epzicom)
Switch to Abacavir/Lamivudine (Epzicom) once daily
03
Endpoints
Primary
Efficacy
Secondary
Safety
Beyond the preview
Go deeper on NCT01608269.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01608269.